112 related articles for article (PubMed ID: 31475315)
1. National trends in metformin-based combination therapy of oral hypoglycaemic agents for type 2 diabetes mellitus.
Kim J; Park S; Kim H; Je NK
Eur J Clin Pharmacol; 2019 Dec; 75(12):1723-1730. PubMed ID: 31475315
[TBL] [Abstract][Full Text] [Related]
2. Second-Line Pharmaceutical Treatments for Patients with Type 2 Diabetes.
Vashisht R; Patel A; Dahm L; Han C; Medders KE; Mowers R; Byington CL; Koliwad SK; Butte AJ
JAMA Netw Open; 2023 Oct; 6(10):e2336613. PubMed ID: 37782497
[TBL] [Abstract][Full Text] [Related]
3. Effects of second-line antihyperglycemic drugs on the risk of chronic kidney disease: applying a target trial approach to a hospital-based cohort of Thai patients with type 2 diabetes.
Siriyotha S; Lukkunaprasit T; Looareesuwan P; Nimitphong H; McKay GJ; Attia J; Thakkinstian A
Cardiovasc Diabetol; 2022 Nov; 21(1):248. PubMed ID: 36397062
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Outcomes After Initiating Triple Antidiabetic Therapy with a GLP-1 RA in an Integrated Health Care System.
Lee SM; Aboubechara N; Niu F; Ledesma VM; Patel YA; Millares M; Hui RL
J Manag Care Spec Pharm; 2019 Mar; 25(3):350-356. PubMed ID: 30816819
[TBL] [Abstract][Full Text] [Related]
5. Patterns of initial and first-intensifying antidiabetic drug utilization among patients with type 2 diabetes mellitus in Scotland, 2010-2020: A retrospective population-based cohort study.
Mahmoud F; Mueller T; Mullen A; Sainsbury C; Rushworth GF; Kurdi A
Diabetes Obes Metab; 2024 Jul; 26(7):2684-2694. PubMed ID: 38558305
[TBL] [Abstract][Full Text] [Related]
6. Changing use of antidiabetic drugs in the UK: trends in prescribing 2000-2017.
Wilkinson S; Douglas I; Stirnadel-Farrant H; Fogarty D; Pokrajac A; Smeeth L; Tomlinson L
BMJ Open; 2018 Jul; 8(7):e022768. PubMed ID: 30056393
[TBL] [Abstract][Full Text] [Related]
7. Persistence of oral antidiabetic treatment for type 2 diabetes characterized by drug class, patient characteristics and severity of renal impairment: A Japanese database analysis.
Kadowaki T; Sarai N; Hirakawa T; Taki K; Iwasaki K; Urushihara H
Diabetes Obes Metab; 2018 Dec; 20(12):2830-2839. PubMed ID: 29974673
[TBL] [Abstract][Full Text] [Related]
8. Sodium-glucose cotransporter 2 inhibitors compared with other glucose-lowering drugs in Japan: Subanalyses of the CVD-REAL 2 Study.
Kohsaka S; Takeda M; Bodegård J; Thuresson M; Kosiborod M; Yajima T; Wittbrodt E; Fenici P
J Diabetes Investig; 2021 Jan; 12(1):67-73. PubMed ID: 32530554
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review of Cost-Effectiveness Studies for the American College of Physicians.
Schousboe JT; Landsteiner A; Drake T; Sultan S; Langsetmo L; Kaka A; Anthony M; Billington CJ; Kalinowski C; Ullman K; Wilt TJ
Ann Intern Med; 2024 May; 177(5):633-642. PubMed ID: 38639547
[TBL] [Abstract][Full Text] [Related]
10. Serum urate change among gout patients treated with sodium-glucose cotransporter type 2 inhibitors vs. sulfonylurea: A comparative effectiveness analysis.
Yokose C; Challener G; Jiang B; Zhou B; McCormick N; Tanikella S; Panchot KMQ; Kohler MJ; Yinh J; Zhang Y; Bates DW; Januzzi JL; Sise M; Wexler D; Choi HK
Semin Arthritis Rheum; 2024 Jun; 66():152441. PubMed ID: 38657403
[TBL] [Abstract][Full Text] [Related]
11. Trends of antidiabetic drug use in adult type 2 diabetes in Korea in 2002-2013: Nationwide population-based cohort study.
Ko SH; Kim DJ; Park JH; Park CY; Jung CH; Kwon HS; Park JY; Song KH; Han K; Lee KU; Ko KS;
Medicine (Baltimore); 2016 Jul; 95(27):e4018. PubMed ID: 27399082
[TBL] [Abstract][Full Text] [Related]
12. Bidirectional modulation of TCA cycle metabolites and anaplerosis by metformin and its combination with SGLT2i.
Harada M; Adam J; Covic M; Ge J; Brandmaier S; Muschet C; Huang J; Han S; Rommel M; Rotter M; Heier M; Mohney RP; Krumsiek J; Kastenmüller G; Rathmann W; Zou Z; Zukunft S; Scheerer MF; Neschen S; Adamski J; Gieger C; Peters A; Ankerst DP; Meitinger T; Alderete TL; de Angelis MH; Suhre K; Wang-Sattler R
Cardiovasc Diabetol; 2024 Jun; 23(1):199. PubMed ID: 38867314
[TBL] [Abstract][Full Text] [Related]
13. Combination therapies with thiazolidinediones are associated with a lower risk of acute exacerbations in new-onset COPD patients with advanced diabetic mellitus: a cohort-based case-control study.
Chen KY; Wu SM; Tseng CH; Lee KY; Lin YH; Liu HY; Chien LN
BMC Pulm Med; 2021 Apr; 21(1):141. PubMed ID: 33926423
[TBL] [Abstract][Full Text] [Related]
14. Time trends and regional variation in utilization of antidiabetic medicines in China, 2015-2022.
Zhang J; Xu S; Liu X; Zhang J; Hu S; Liu X; Yang C; Fang Y
Diabetes Obes Metab; 2024 Jul; 26(7):2752-2760. PubMed ID: 38618979
[TBL] [Abstract][Full Text] [Related]
15. Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta-analysis.
Kamalinia S; Josse RG; Donio PJ; Leduc L; Shah BR; Tobe SW
Endocrinol Diabetes Metab; 2020 Jan; 3(1):e00100. PubMed ID: 31922027
[TBL] [Abstract][Full Text] [Related]
16. Canagliflozin/metformin Fixed-dose Combination: National Evidence, Global Relevance.
Kalra S; Kapoor N
J Assoc Physicians India; 2024 Apr; 72(4):11. PubMed ID: 38881076
[No Abstract] [Full Text] [Related]
17. Deciphering mortality risk of diabetes medications in heart failure patients with diabetes mellitus under triple guideline-directed medical therapy.
Çöllüoğlu İT; Çelik A; Ata N; Ural D; Şahin A; Ulgu MM; Kanık EA; Birinci Ş; Yılmaz MB
Int J Cardiol; 2024 Jul; 407():132109. PubMed ID: 38703896
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with choice of intensification treatment for type 2 diabetes after metformin monotherapy: a cohort study in UK primary care.
Wilkinson S; Douglas IJ; Williamson E; Stirnadel-Farrant HA; Fogarty D; Pokrajac A; Smeeth L; Tomlinson LA
Clin Epidemiol; 2018; 10():1639-1648. PubMed ID: 30519112
[TBL] [Abstract][Full Text] [Related]
19. Durability of initial antidiabetic monotherapy and subsequent treatment adjustment patterns among newly treated type 2 diabetes patients.
Noh Y; Lee S; Shin S
Ther Clin Risk Manag; 2018; 14():1563-1571. PubMed ID: 30233191
[TBL] [Abstract][Full Text] [Related]
20. Metabolic effects of SGLT2i and metformin on 3-hydroxybutyric acid and lactate in db/db mice.
Harada M; Han S; Shi M; Ge J; Yu S; Adam J; Adamski J; Scheerer MF; Neschen S; de Angelis MH; Wang-Sattler R
Int J Biol Macromol; 2024 Apr; 265(Pt 1):130962. PubMed ID: 38503370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
